155 related articles for article (PubMed ID: 36709166)
1. [Effect of ruxolitinib combined with glucocorticoid on cytomegalovirus activation in acute graft-versus-host disease].
Xing SY; Qian K; Zhao YX; Peng B; Yang JJ; Dou LP; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):732-737. PubMed ID: 36709166
[No Abstract] [Full Text] [Related]
2. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
3. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group.
Bueno F; Solano C; Vázquez L; Giménez E; de la Cámara R; Albert E; Rovira M; Espigado I; Martín Calvo C; López-Jiménez J; Suárez-Lledó M; Chinea A; Esquirol A; Pérez A; Bermúdez A; Saldaña R; Heras I; González-Huerta AJ; Torrado T; Batlle M; Jiménez S; Vallejo C; Barba P; Cuesta MÁ; Duarte R; Piñana JL; Navarro D;
Transpl Infect Dis; 2021 Aug; 23(4):e13627. PubMed ID: 33908148
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease.
Cantoni N; Hirsch HH; Khanna N; Gerull S; Buser A; Bucher C; Halter J; Heim D; Tichelli A; Gratwohl A; Stern M
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1309-14. PubMed ID: 20353832
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
[TBL] [Abstract][Full Text] [Related]
8. [Cytomegalovirus infection monitoring in patients with long-term survival after allogeneic hematopoietic stem cell transplantation].
Chen L; Luo Y; Hu Y; Tan Y; Zhao Y; Fan J; Huang H
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3145-9. PubMed ID: 25573309
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia.
Lin F; Dong X; Zhang Y; Cheng Y; Han T; Mo X; Fu H; Han W; Wang F; Tang F; Yan C; Sun Y; Xu Z; Wang Y; Zhang X; Huang X; Xu L
Ann Hematol; 2023 Sep; 102(9):2589-2598. PubMed ID: 37438489
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of risk factors and prognosis of cytomegalovirus infection post umbilical cord blood stem cell transplantation in children with primary immunodeficiency diseases].
Wei ZL; Qian XW; Wang P; Jiang WJ; Wang HS; Shen C; Wang WJ; Hou J; Wang YH; Huang Y; Wang XC; Zhai XW
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1019-1025. PubMed ID: 36207848
[No Abstract] [Full Text] [Related]
11. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.
Tang Y; Yang D; Xie R; Zhong Z; You Y
Transpl Immunol; 2023 Feb; 76():101743. PubMed ID: 36372140
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Study of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation].
Xiong YY; Liu L; Chen JB; Tang XQ; Xiao Q; Zhang HB; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):513-521. PubMed ID: 37096528
[TBL] [Abstract][Full Text] [Related]
14. Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric β-Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study.
Hong X; Chen Y; Lu J; Lu Q
Pediatr Transplant; 2023 Mar; 27(2):e14466. PubMed ID: 36597217
[TBL] [Abstract][Full Text] [Related]
15. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
[TBL] [Abstract][Full Text] [Related]
16. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between human herpesvirus 6 activation and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Wang LR; Dong LJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):507-10. PubMed ID: 17172120
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
Resende CB; Rezende BM; Bernardes PT; Teixeira GM; Teixeira MM; Pinho V; Bittencourt H
Braz J Med Biol Res; 2017 Feb; 50(2):e5566. PubMed ID: 28198910
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of the usefulness of letermovir for prevention of cytomegalovirus infection after haploidentical hematopoietic stem cell transplantation].
Ma R; He Y; Wang HF; Bai L; Han W; Cheng YF; Liu KY; Xu LP; Zhang XH; Wang Y; Zhang YY; Wang FR; Mo XD; Yan CH; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):826-832. PubMed ID: 37394853
[No Abstract] [Full Text] [Related]
20. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
